PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Microbiology, Boston University School of Medicine, Boston, MA, United States.\', \'Department of Medicine, Boston University School of Medicine, Boston, MA, United States.\', \'PiBS Program, Boston University School of Medicine, Boston, MA, United States.\', \'Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, MA, United States.\', \'National Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA, United States.\', \'Flow Cytometry Core Facility, Boston University School of Medicine, Boston, MA, United States.\', \'Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, United States.\', \'Center for Regenerative Medicine, Boston University School of Medicine, Boston, MA, United States.\', \'Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA, United States.\', \'Renal Section, Department of Medicine, VA Boston Healthcare System, Boston, MA, United States.\', \'MilliporeSigma, Burlington, MA, United States.\', \'Antagen Pharmaceuticals, Boston, MA, United States.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.3389/fimmu.2021.614676
?:doi
?:hasPublicationType
?:journal
  • Frontiers in immunology
is ?:pmid of
?:pmid
?:pmid
  • 33897682
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.803
?:rankingScore_hIndex
  • 69
is ?:relation_isRelatedTo_publication of
?:title
  • Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all